Gallbladder cancer - null regimens
Jump to navigation
Jump to search
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main gallbladder cancer page for current regimens.
Neoadjuvant therapy
No neoadjuvant therapy
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Awaiting publication (ECOG-ACRIN EA2197) | 2020-ongoing | Phase 3 (C) | GC | In progress |
No systemic therapy prior to surgery.
Subsequent treatment
References
- ECOG-ACRIN EA2197: NCT04559139
Metastatic or unresectable disease, all lines of therapy
Best supportive care
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Sharma et al. 2010 | 2006-2008 | Randomized (C) | 1. FUFA | Did not meet primary endpoint of OS |
| 2. mGEMOX | Seems to have inferior OS |
No active antineoplastic treatment.
References
- Sharma A, Dwary AD, Mohanti BK, Deo SV, Pal S, Sreenivas V, Raina V, Shukla NK, Thulkar S, Garg P, Chaudhary SP. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol. 2010 Oct 20;28(30):4581-6. Epub 2010 Sep 20. link to original article contains dosing details in abstract PubMed